NCT05329038 is a Phase 4 clinical trial of Inactivated COVID-19 Vaccine in COVID-19, sponsored by Sinovac Life Sciences Co., Ltd..

Who is sponsoring NCT05329038?

NCT05329038 is sponsored by Sinovac Life Sciences Co., Ltd..

What drugs are being tested in NCT05329038?

Interventions in NCT05329038: Inactivated COVID-19 Vaccine.

Is NCT05329038 still recruiting?

NCT05329038 is currently status unknown. Last updated 7 November 2023.

Last reviewed 2023-11-07 · How we verify

NCT05329038

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine

Status unknown Phase 4 Last updated 7 November 2023

What this trial tests

Phase 4 trial testing Inactivated COVID-19 Vaccine in COVID-19 in 180 participants. Status unknown.

Timeline

19 April 2022

Primary endpoint
19 June 2022

20 February 2024

Quick facts

Lead sponsor	Sinovac Life Sciences Co., Ltd.
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	180
Start date	19 April 2022
Primary completion	19 June 2022
Estimated completion	20 February 2024
Sites	1 location across China

Drugs / interventions tested

Inactivated COVID-19 Vaccine — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Sinovac Life Sciences Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase Ⅳ follow-up clinical trial based on the previous Phase Ⅳ clinical trial of an inactivated COVID-19 vaccine (CoronaVac) manufactured by Sinovac Life Sciences Co., Ltd.The purpose of this study is to evaluate the immunogenicity,safety and cross-immune response of booster immunization using COVID-19 vaccine,to compare the similarities and differences of immune responses between primary immunization and booster immunization and to detect antibody against hepatitis A and evaluate the immune persistence of the one dose immunization schedule of hepatitis A vaccine in healthy population aged 18 years and older.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Current clinical status of new COVID-19 vaccines and immunotherapy.
Nagpal D, Nagpal S, Kaushik D, Kathuria H. · · 2022 · cited 6× · PMID 36063274 · DOI 10.1007/s11356-022-22661-1

Verify or expand the search:

Other trials of Inactivated COVID-19 Vaccine

Trials testing the same drug.

NCT05198336 — Immunogenicity of an Inactivated COVID-19 Vaccine · Phase 4 · completed
NCT04992260 — Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents · Phase 3 · completed
NCT04974164 — Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic · completed
NCT04953325 — Immunogenicity and Safety of an Inactivated COVID-19 Vaccine · Phase 4 · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Sinovac Life Sciences Co., Ltd. trials

Trials by the same sponsor.

NCT07374510 — Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine · Phase 1 · not yet recruiting
NCT06967272 — PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) · Phase 2 · recruiting
NCT06617715 — Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine · Phase 3 · recruiting
NCT06550830 — Clinical Trial of PCV24 in Children Aged 2-17 Years · Phase 1 · completed
NCT06474377 — Clinical Trial of PCV24 in Adults · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05329038 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sinovac Life Sciences Co., Ltd.
Last refreshed: 7 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05329038.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing